Medical Device Development: Point-Counterpoint
Executive SummaryIndustry and government met to share common perspectives at the inaugural Cleveland Clinic Foundation's Medical Innovation Summit, held this past October, entitled "Bench to Boardroom to Patient Bedside: The Need for Speed." But barely below the surface were striking disagreements about where the fault lies for what all agreed is a disappointingly poor record of device innovation in recent years.
You may also be interested in...
Japanese firm in discussions with regulator as high-need novel therapy for spinocerebellar degeneration misses endpoint but shows promise in pooled analysis.
The FDA has readied plans for hastened emergency-use approvals of coronavirus test kits after an infected US citizen returned to Washington State from Wuhan province in China. See what the FDA’s Megan McSeveney said about it here.
Despite obvious similarities in the contentious reviews of Sarepta’s Vyondys 53 and its predecessor Exondys 51, drug developers should focus on the differences between the two reviews.